- Home
- GRAF vs YMAB Comparison
GRAF vs YMAB Comparison
Compare GRAF & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRAF
- YMAB
- Stock Information
- Founded
- GRAF 2021
- YMAB 2015
- Country
- GRAF United States
- YMAB United States
- Employees
- GRAF N/A
- YMAB N/A
- Industry
- GRAF
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GRAF
- YMAB Health Care
- Exchange
- GRAF NYSE
- YMAB Nasdaq
- Market Cap
- GRAF 292.7M
- YMAB 270.5M
- IPO Year
- GRAF 2024
- YMAB 2018
- Fundamental
- Price
- GRAF $10.22
- YMAB $4.88
- Analyst Decision
- GRAF
- YMAB Buy
- Analyst Count
- GRAF 0
- YMAB 11
- Target Price
- GRAF N/A
- YMAB $19.64
- AVG Volume (30 Days)
- GRAF 3.9K
- YMAB 333.1K
- Earning Date
- GRAF 01-01-0001
- YMAB 03-04-2025
- Dividend Yield
- GRAF N/A
- YMAB N/A
- EPS Growth
- GRAF N/A
- YMAB N/A
- EPS
- GRAF 0.30
- YMAB N/A
- Revenue
- GRAF N/A
- YMAB $87,685,000.00
- Revenue This Year
- GRAF N/A
- YMAB $20.07
- Revenue Next Year
- GRAF N/A
- YMAB $8.76
- P/E Ratio
- GRAF $33.39
- YMAB N/A
- Revenue Growth
- GRAF N/A
- YMAB 3.38
- 52 Week Low
- GRAF $9.03
- YMAB $4.25
- 52 Week High
- GRAF $11.02
- YMAB $17.78
- Technical
- Relative Strength Index (RSI)
- GRAF N/A
- YMAB 40.52
- Support Level
- GRAF N/A
- YMAB $4.45
- Resistance Level
- GRAF N/A
- YMAB $5.03
- Average True Range (ATR)
- GRAF 0.00
- YMAB 0.39
- MACD
- GRAF 0.00
- YMAB 0.02
- Stochastic Oscillator
- GRAF 0.00
- YMAB 48.15
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.